We deimmunized a clinical CD19 CAR binder with experimentally detected HLA-I epitope depletion while retaining tumor killing, and rescued a secreted protease to function in the cytosol.
Both done with one unified design framework: ProVADA.
How it works and what we tested 🧵 (1/11)